GLP-1 Online: Best Telehealth Providers Compared (2026 Guide)

Buying a GLP-1 online in 2023 meant choosing between Ro, a few startups, and a long tail of compounding-pharmacy services that filled prescriptions in 48 hours for cash. The market in 2026 looks completely different. The FDA cleared tirzepatide off the shortage list in December 2024 and semaglutide in February 2025, ending the legal cover that powered mass compounding. On September 16, 2025 the FDA sent warning letters to more than 55 telehealth companies for illegally marketing compounded GLP-1s. On March 9, 2026, Hims settled with Novo Nordisk, dropped compounded semaglutide, and became a paid telehealth channel for branded Wegovy. The result: a smaller, more split, and frankly more honest market.

Direct answer: As of May 2026, GLP-1 telehealth options split into two camps. The branded-only group — Ro ($149/month membership), Hims ($149/month), WeightWatchers Clinic ($74–$149/month), Calibrate (~$199/month), and Form ($179/month) — sells FDA-approved Wegovy ($199–$349/month), Zepbound ($299–$549/month), oral Wegovy ($149–$249/month), and Foundayo, runs prior-authorization workflows, and connects manufacturer savings cards that drop insured medication cost to $0–$25/month. The compounded-focused group — Henry Meds ($197–$449/month bundled), Mochi ($178/month total), Eden ($149–$196/month), and Shed (variable) — sells 503A-compounded semaglutide or tirzepatide cash, no insurance involved. Cheapest is rarely the best clinical fit, and the compounded group now operates under documented-medical-necessity rules rather than the old shortage exemption.

What Changed in 2024-2026

The compounded GLP-1 market is a fraction of what it was 18 months ago. A condensed timeline:

Date	Event
December 2024	FDA resolves tirzepatide shortage
February 2025	FDA resolves semaglutide shortage
May 2025	Grace period for mass-compounded GLP-1s ends
September 9, 2025	FDA/HHS announce broad enforcement on misleading DTC pharma ads (~100 cease-and-desist letters)
September 16, 2025	FDA sends 55+ warning letters to telehealth companies marketing compounded GLP-1s
January 2026	Novo launches branded oral Wegovy at $149/month starter
February 5, 2026	Hims announces $49 compounded semaglutide pill
February 9, 2026	Novo Nordisk sues Hims for patent infringement
March 9, 2026	Novo drops lawsuit; Hims agrees to stop promoting compounded GLP-1s and offer branded at telehealth-standard pricing
April 2026	FDA approves Foundayo (orforglipron), first non-peptide oral GLP-1
Mid-2026 (target)	Hims completes compounded exit; existing patients transitioned

The legal framework matters. Compounded GLP-1s are now sold only under 503A pharmacy compounding rules — each prescription must document a specific clinical need (dose unavailable commercially, allergy to an excipient, etc.) rather than ride a blanket shortage exemption. Mass compounding for general weight loss is the basis of the FDA letters.

The 9 Telehealth Providers Worth Comparing

Branded-Only Providers

These charge a membership fee on top of the medication and run insurance benefit checks. Best for patients with commercial coverage or for self-pay patients who want full-label drugs.

Provider	Membership	Medications offered	Self-pay medication price	Notable
Ro	$39 month 1, $74-$149/mo ongoing	Wegovy, oral Wegovy, Zepbound	$199-$349 Wegovy; $299-$449 Zepbound	Insurance concierge handles PA
Hims	$39 month 1, $149/mo ongoing	Wegovy, oral Wegovy, Zepbound, Ozempic	$249-$399	Authorized Novo channel post-settlement
WeightWatchers Clinic (Sequence)	$25/mo first 3 mo (12-mo plan), $74/mo after; $149/mo month-to-month	Wegovy, Zepbound, oral Wegovy (Med+)	$199 intro then $349 Wegovy; $149 oral Wegovy at low doses	Strong PA team
Calibrate	~$199/mo (annual plan)	Wegovy, Zepbound	Insurance preferred	One-year program with coaching
Form	$179/mo	Wegovy, Zepbound	Insurance preferred	Board-certified obesity medicine

Compounded-Focused Providers

These bundle medication, provider visit, and shipping into one cash price. No insurance billing. All-in pricing is generally cheaper than branded self-pay, but with the trade-offs of compounded medication.

Provider	All-in monthly cost	Medications offered	Notable
Henry Meds	$197 (annual prepay) - $449	Compounded sema (inj + oral), compounded tirz (inj + oral)	$179 entry pricing actually for liraglutide
Mochi Health	$178/mo total ($99 med + $79 membership)	Compounded sema (4 formats), compounded tirz, brand-name	Flat pricing across doses
Eden	$149-$196/mo	Compounded sema + tirz, some brand-name	Flat pricing across doses
Shed	$179-$249/mo first month	Brand-name + compounded under one program	Weight-loss guarantee marketing

Real Out-of-Pocket Cost Scenarios

The advertised price almost never matches the wallet hit. Three realistic scenarios:

Scenario A: Commercial Insurance + Branded GLP-1

Provider membership: $74-$199/month
Wegovy or Zepbound after insurance + manufacturer savings card: $0-$25/month
Total typical: $74-$224/month

This is the cheapest path if your plan covers obesity medication. Ro, Hims, and WeightWatchers Clinic each run prior-authorization workflows.

Scenario B: Self-Pay Branded

Provider membership: $74-$199/month
Wegovy: $199-$349/month; oral Wegovy: $149-$249/month; Zepbound: $299-$549/month
Total typical: $273-$748/month

This is the option for patients without obesity coverage who still want full-label medication. Cash pricing has come down: Wegovy starter pens are $199/month, and oral Wegovy 1.5-4 mg is $149/month through Novo's NovoCare cash channel and WeightWatchers Med+.

Scenario C: Self-Pay Compounded

All-in (medication + visit + shipping): $149-$329/month, generally
Higher tirzepatide doses can push Henry Meds to $449/month

Often the cheapest path overall, but with the regulatory and quality uncertainties that came into sharper focus after the September 2025 FDA enforcement wave.

Branded vs Compounded: The Decision That Matters Most

Factor	Branded (Wegovy, Zepbound, oral Wegovy, Foundayo)	Compounded semaglutide or tirzepatide
FDA-approved	Yes	No (compounded under 503A)
Manufacturer	Novo Nordisk or Eli Lilly	State-licensed compounding pharmacy
Quality control	FDA inspection + manufacturer	State board + pharmacy QA
Legal status post-shortage	Standard	Legal only with documented patient-specific need
Insurance coverage	Often (with PA)	Almost never
Self-pay starting price	$149-$549/month	$99-$329/month (bundled)
Long-term supply	Reliable	Subject to enforcement and lawsuits
Best for	Insured patients, self-pay who want full label	Self-pay patients who accept the trade-offs

The FDA was explicit in its September 2025 announcement. The agency cited telehealth marketing that "falsely suggests compounded GLP-1s are identical to approved products and misrepresents sourcing, reinforcing that compounded drugs bypass FDA premarket safety, efficacy, and quality review." That language matters because it tells you what the regulator views as misleading — claims of identity with the branded drug, claims about pharmaceutical-grade sourcing, claims about FDA equivalence. None of those claims hold up.

The compounded product can still be a reasonable choice for an uninsured patient who would otherwise not get treatment. It is not a reasonable choice for a patient who can get the branded version for $25/month with insurance.

Provider Deep Dives

Ro

The polished default for branded GLP-1. Membership is $39 the first month, then $74/month on annual prepay or $149/month on a month-to-month plan. Wegovy pens are $199/month for the first two months and $349/month thereafter when self-pay; Zepbound is $299-$449/month depending on dose. Ro's main advantage is its insurance concierge team, which runs prior authorization paperwork and applies Novo and Lilly savings cards. For insured patients this turns a $500+ medication bill into a $0-$25 copay. For self-pay, Ro is similar in cost to going through any clinic.

Hims

Was the largest compounded-semaglutide seller in 2024-2025. After the March 9, 2026 Novo settlement, Hims stopped advertising compounded GLP-1 and became an authorized telehealth channel for branded Wegovy, oral Wegovy, Ozempic, and Zepbound. Membership is $39 the first month, $149/month after that. Wegovy and Ozempic are priced at "telehealth-standard" rates per the settlement. Existing compounded patients are being transitioned through mid-2026. Hims has no video consultations, no required labs, and no obesity-medicine specialists — clinical interaction is text-only.

WeightWatchers Clinic (formerly Sequence)

WW acquired Sequence for $132 million in 2023 and rebranded it as WW Clinic. The introductory pricing is the lowest on the branded side: $25/month for the first 3 months on a 12-month plan, then $74/month for the rest of the year. Month-to-month is $149/month. Through August 31, 2026, oral Wegovy 1.5-4 mg is $149/month through WW Med+ for eligible self-pay patients. Self-pay Wegovy and Ozempic pens are $199/month introductory through March 31, 2026, then $349/month. The care team handles insurance PA. The best fit for patients who want structured behavioral support alongside medication.

Calibrate

Twelve-month metabolic-reset program at roughly $199/month on annual prepay. Heavier emphasis on coaching and lifestyle integration than the strictly transactional services. Branded only. Best for patients who want a full-program structure rather than a pure prescription service.

Form

Smaller, physician-led, branded only. $179/month membership. Marketed on the strength of its prescribing clinicians — board-certified in obesity medicine — which is unusual in this category. Best for patients who want a higher clinical bar without paying boutique-clinic prices.

Henry Meds

Has avoided FDA warning letters so far. All-in pricing is the marketing hook: provider visit, supplies, and shipping bundled into one monthly fee. Real prices are higher than the homepage suggests — the advertised "$179/month" is for liraglutide or a 12-month prepay on injectable semaglutide. Standard month-to-month compounded semaglutide injection is $297/month (or $247 first month), oral semaglutide is $249/month, injectable tirzepatide is $449/month, and oral tirzepatide is $349/month. No labs required at intake.

Mochi Health

Flat-rate compounded pricing — $99/month for compounded semaglutide injection regardless of dose, plus a $79/month membership for a $178/month total. Tirzepatide is $199/month flat. Strengths include video consultations with board-certified obesity medicine physicians and the widest medication selection in the compounded space (semaglutide as injection, oral tablet, oral drops, and microdose). Concerns include an active Eli Lilly lawsuit over compounded tirzepatide marketing and a 2025 pharmacy partner that was shut down for unsafe compounding practices.

Eden

Flat upfront pricing that does not change with dose. $149-$196/month for compounded products. Also lists brand-name medications (Mounjaro, Ozempic, Victoza, Wegovy, Zepbound). Eden's self-reported member data shows an average of 29.3 lbs lost in 6 months across 111 members — directionally consistent with clinical trial averages.

Shed

A newer entrant pitching brand-name plus compounded under one program with a weight-loss guarantee. Reviewer ratings are favorable but the model is unverified at scale. Compounded options still lack FDA premarket approval; cash-pay only; state coverage varies.

A Reasonable Decision Tree

Step 1: Do you have commercial insurance with obesity coverage?

Yes → WeightWatchers Clinic, Ro, or Hims. Their PA teams get most insured patients to $0-$25 medication + a $74-$149 membership.
No → continue to Step 2.

Step 2: Can you afford $300-$500/month for branded medication?

Yes → Ro Wegovy at $199 starter, or oral Wegovy at $149/month through Med+. Predictable supply, full label.
No → continue to Step 3.

Step 3: Are you willing to use a 503A-compounded GLP-1?

Yes → Mochi ($178 total) or Eden ($149-$196) are the cheapest with decent quality signals. Henry Meds is more expensive month to month but established.
No → look at manufacturer cash programs (NovoCare, LillyDirect Zepbound vials) which now overlap compounded pricing for low doses.

Quality Signals That Matter

Things to verify before signing up with any provider:

A licensed clinician evaluates you — not just a form review by an algorithm
Labs ordered before the first prescription — the gold standard, especially for patients with thyroid, kidney, or pancreatic history
Pharmacy name is shared — branded: standard retail. Compounded: ask for the pharmacy and the state. State board action against the pharmacy in the last 24 months is a red flag.
Video or phone access during titration — text-only support is normal but limiting when nausea spikes at week 4
Discontinuation policy is reasonable — patients are not flight risks. Look for clean cancel flows.
Membership renewal is transparent — most auto-renew; set a calendar reminder when you sign up
Return policy on medication — compounded medication is generally not returnable; budget accordingly

Red Flags

"Limited slots" or countdown timers
No labs requested, even when you offer to provide them
One-size-fits-all dosing protocols with no clinician input
Communication via unencrypted SMS only
Pharmacy name not disclosed before purchase
Prescriber credentials not disclosed
Prescription written within minutes of a questionnaire submission
Auto-renew that requires phone calls to cancel
Marketing that claims the compounded product is "identical to" or "the same as" brand-name Wegovy or Zepbound — that is the exact language the FDA cited in its September 2025 warning letters

What Telehealth Cannot Do Well

Complex medical histories — prior pancreatitis, heart failure, advanced CKD, or thyroid history needs an in-person specialist
Children and teens — most platforms exclude under-18s
Pregnancy planning — semaglutide and tirzepatide need a 2-month washout before conception. Better managed by a coordinated team.
Polypharmacy with many interactions — coordination is hard when the GLP-1 prescriber never sees your other meds
Patients on Medicare — the membership fee is wasted money for most Medicare beneficiaries who have a covered provider

What People Get Wrong About Online GLP-1

"Compounded telehealth GLP-1 is the same drug as the pharmacy version." It is not. Compounded semaglutide is a legally distinct formulation made by a 503A pharmacy. The FDA has been explicit that this claim is misleading.
"The shortage is back, so compounding is legal again." It is not. FDA cleared both shortages and the grace period ended in May 2025. Compounding now requires documented patient-specific need.
"Hims still sells $49 compounded sema." Not since March 9, 2026. The settlement with Novo Nordisk ended that.
"All telehealth providers are basically equivalent." Pricing, clinical depth, supply chain, and regulatory exposure vary widely.
"I can just stop paying and the membership will go away." Auto-renew is the norm. Cancel explicitly through the dashboard.
"Cheaper is always better." A $99 compounded plan with no labs and no after-hours support can be worse than a $200 branded plan with proper care.

Frequently Asked Questions

Can I get a GLP-1 prescription entirely online in 2026? Yes. Major telehealth platforms (Ro, Hims, WeightWatchers Clinic, Calibrate, Form) write prescriptions for branded Wegovy, Zepbound, oral Wegovy, and Foundayo. Compounded providers (Henry Meds, Mochi, Eden, Shed) write prescriptions for 503A-compounded semaglutide or tirzepatide. State availability varies.

Is online GLP-1 cheaper than going to a doctor in person? Not always. With commercial insurance and a savings card, your primary care doctor can usually get you the same $0-$25 medication price without a $149 membership fee. Telehealth wins on speed and on bundled compounded pricing for self-pay patients.

Are compounded GLP-1s still available online after FDA cleared the shortages? Yes, but under stricter rules. The mass-compounding exemption ended in May 2025. 503A pharmacy compounding now requires a documented patient-specific medical need — e.g., a dose not commercially available or a documented allergy to an excipient — rather than a blanket shortage justification.

Which telehealth provider has the cheapest GLP-1? For insured patients: WeightWatchers Clinic ($25/month membership intro). For self-pay compounded: Mochi at $178/month all-in. For self-pay branded: Novo's NovoCare cash pricing or Ro's $199 Wegovy starter.

Does insurance cover online GLP-1 prescriptions? For branded medications, yes — about 50-60% of commercial plans cover Wegovy or Zepbound for obesity, with prior authorization. Compounded GLP-1s are almost never covered.

Is it safe to buy GLP-1 from a telehealth provider? The reputable end of the market — providers with licensed clinicians, identifiable pharmacies, and proper screening — is safe. The risky end is the providers that received FDA warning letters in September 2025 and the ones that continue to make claims of identity with branded drugs.

Did Hims really exit compounded GLP-1? For new patients, yes, as of March 9, 2026. Existing patients are being transitioned to branded products through mid-2026 under the settlement terms with Novo Nordisk.

What is the difference between Sequence and WeightWatchers Clinic? Same thing. WW acquired Sequence in 2023 and rebranded the service as WW Clinic. The joinsequence.com domain redirects to the WeightWatchers clinic page.

Can I cancel my GLP-1 telehealth membership easily? Most providers allow cancellation through the account dashboard, but auto-renew is universal. Cancel explicitly, save the confirmation email, and watch your next statement.

Last reviewed: May 13, 2026

GLP-1 Online: The 9 Telehealth Providers Worth Knowing in 2026